Benzinga | Nov 19, 2021 05:37AM EST

BMO Capital Initiates Coverage On Bristol-Myers Squibb with Outperform Rating, Announces Price Target of $72

BMO Capital analyst Evan Seigerman initiates coverage on Bristol-Myers Squibb (NYSE:BMY) with a Outperform rating and announces Price Target of $72.